Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

Phase 3

Completed

Conditions: Kidney Cancer

Interventions: Biological: dactinomycin
Biological: filgrastim
Drug: cyclophosphamide
Drug: carboplatin
Drug: doxorubicin hydrochloride
Procedure: conventional surgery
Drug: etoposide
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-07-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 203

Registration Number: NCT00002610

Locations: 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Floating Hospital for Children, Boston, Massachusetts, United States

and more 231 locations

4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

Phase 3

Terminated

Conditions: Bladder Cancer

Interventions: Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: vinblastine

First Posted Date: 2003-01-27

Last Posted Date: 2017-06-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 521

Registration Number: NCT00005047

Locations: 🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸
Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States
🇺🇸
William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States

and more 71 locations

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-15

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 475

Registration Number: NCT00004179

Locations: 🇳🇱
Amphia Ziekenhuis - locatie Molengracht, Breda, Netherlands
🇳🇱
Reinier de Graaf Group - Delft, Delft, Netherlands
🇿🇦
Sandton Oncology Centre, Johannesburg, South Africa

and more 256 locations

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT00005822

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: mesna
Drug: melphalan
Drug: paclitaxel
Drug: tamoxifen citrate
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Procedure: conventional surgery

First Posted Date: 2003-01-27

Last Posted Date: 2024-04-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 41

Registration Number: NCT00003042

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: leucovorin calcium
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 79

Registration Number: NCT00020943

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States

and more 78 locations

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: paclitaxel
Procedure: conventional surgery

First Posted Date: 2003-01-27

Last Posted Date: 2017-07-31

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 82

Registration Number: NCT00006110

Locations: 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: CHOP regimen
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Radiation: radiation therapy
Drug: vincristine sulfate

First Posted Date: 2003-01-27

Last Posted Date: 2021-05-18

Lead Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group

Target Recruit Count: 1506

Registration Number: NCT00052936

Locations: 🇩🇪
Onkologische Schwerpunktpraxis, Hildesheim, Germany
🇩🇪
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany
🇩🇪
General Hospital, Celle, Germany

and more 160 locations

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2019-08-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 393

Registration Number: NCT00004228

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States

and more 172 locations

Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Scotland and Newcastle Lymphoma Group

Registration Number: NCT00003815

Locations: 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy